David Kaysen has more than 35 years of experience leading and managing domestic and international emerging growth companies including biopharmaceutical, medical device, and clinical software/IT companies. He is experienced in the FDA approval process, leading products in revenue growth, and has experience in Australia.
Prior to becoming the chief executive and managing director of Medibio from November 2018 to February 2019, Mr Kaysen was the president, chief executive and director of Sun BioPharma (a biopharmaceutical company developing a drug for pancreatic cancer), Uroplasty (a publicly traded global medical device company), Advanced Duplications Services, Diametrics Medical, and Rehabilicare. Mr Kaysen also served on the boards of Sun BioPharma, InterRad Medical, Spinal Singularity, Atlantic Therapeutics, and EXB Solutions.
